JP6521956B2 - 性染色体におけるコピー数変異を判定するための方法 - Google Patents
性染色体におけるコピー数変異を判定するための方法 Download PDFInfo
- Publication number
- JP6521956B2 JP6521956B2 JP2016521519A JP2016521519A JP6521956B2 JP 6521956 B2 JP6521956 B2 JP 6521956B2 JP 2016521519 A JP2016521519 A JP 2016521519A JP 2016521519 A JP2016521519 A JP 2016521519A JP 6521956 B2 JP6521956 B2 JP 6521956B2
- Authority
- JP
- Japan
- Prior art keywords
- chromosome
- sequence
- sample
- test sample
- sequencing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000000349 chromosome Anatomy 0.000 title claims description 570
- 238000000034 method Methods 0.000 title claims description 345
- 230000035772 mutation Effects 0.000 title description 22
- 230000001568 sexual effect Effects 0.000 title 1
- 239000000523 sample Substances 0.000 claims description 574
- 238000012360 testing method Methods 0.000 claims description 305
- 238000012163 sequencing technique Methods 0.000 claims description 260
- 210000002593 Y chromosome Anatomy 0.000 claims description 234
- 150000007523 nucleic acids Chemical class 0.000 claims description 218
- 102000039446 nucleic acids Human genes 0.000 claims description 204
- 108020004707 nucleic acids Proteins 0.000 claims description 204
- 208000036878 aneuploidy Diseases 0.000 claims description 179
- 231100001075 aneuploidy Toxicity 0.000 claims description 171
- 230000001605 fetal effect Effects 0.000 claims description 148
- 230000008774 maternal effect Effects 0.000 claims description 130
- 238000012549 training Methods 0.000 claims description 118
- 210000004027 cell Anatomy 0.000 claims description 75
- 230000000873 masking effect Effects 0.000 claims description 71
- 238000009826 distribution Methods 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 38
- 210000003754 fetus Anatomy 0.000 claims description 32
- 230000008569 process Effects 0.000 claims description 30
- 238000011156 evaluation Methods 0.000 claims description 23
- 238000003860 storage Methods 0.000 claims description 12
- 238000004590 computer program Methods 0.000 claims description 11
- 238000007689 inspection Methods 0.000 claims description 11
- 230000015654 memory Effects 0.000 claims description 7
- 238000000638 solvent extraction Methods 0.000 claims description 4
- 239000013068 control sample Substances 0.000 claims description 3
- 102000053602 DNA Human genes 0.000 description 195
- 108020004414 DNA Proteins 0.000 description 195
- 230000002759 chromosomal effect Effects 0.000 description 164
- 238000004458 analytical method Methods 0.000 description 86
- 239000003550 marker Substances 0.000 description 69
- 241000282414 Homo sapiens Species 0.000 description 60
- 239000012634 fragment Substances 0.000 description 51
- 239000000203 mixture Substances 0.000 description 47
- 238000012217 deletion Methods 0.000 description 45
- 230000037430 deletion Effects 0.000 description 45
- 210000004369 blood Anatomy 0.000 description 44
- 239000008280 blood Substances 0.000 description 44
- 210000002381 plasma Anatomy 0.000 description 42
- 208000037280 Trisomy Diseases 0.000 description 41
- 208000026928 Turner syndrome Diseases 0.000 description 41
- 230000035945 sensitivity Effects 0.000 description 39
- 238000012545 processing Methods 0.000 description 38
- 201000010374 Down Syndrome Diseases 0.000 description 37
- 206010044688 Trisomy 21 Diseases 0.000 description 35
- 208000016679 Monosomy X Diseases 0.000 description 33
- 238000003745 diagnosis Methods 0.000 description 33
- 239000002773 nucleotide Substances 0.000 description 33
- 125000003729 nucleotide group Chemical group 0.000 description 33
- 230000036961 partial effect Effects 0.000 description 32
- 230000003321 amplification Effects 0.000 description 27
- 238000007481 next generation sequencing Methods 0.000 description 27
- 238000003199 nucleic acid amplification method Methods 0.000 description 27
- 102000040430 polynucleotide Human genes 0.000 description 27
- 108091033319 polynucleotide Proteins 0.000 description 27
- 239000002157 polynucleotide Substances 0.000 description 27
- 208000011580 syndromic disease Diseases 0.000 description 27
- 210000001766 X chromosome Anatomy 0.000 description 26
- 238000012369 In process control Methods 0.000 description 25
- 239000012472 biological sample Substances 0.000 description 25
- 210000004544 dc2 Anatomy 0.000 description 25
- 238000005516 engineering process Methods 0.000 description 25
- 238000004190 ion pair chromatography Methods 0.000 description 25
- 238000002360 preparation method Methods 0.000 description 25
- 238000010606 normalization Methods 0.000 description 24
- 238000001914 filtration Methods 0.000 description 23
- 239000011324 bead Substances 0.000 description 20
- 239000000047 product Substances 0.000 description 20
- 238000013507 mapping Methods 0.000 description 19
- 206010053884 trisomy 18 Diseases 0.000 description 19
- 208000031639 Chromosome Deletion Diseases 0.000 description 18
- 201000006360 Edwards syndrome Diseases 0.000 description 18
- 108091028043 Nucleic acid sequence Proteins 0.000 description 18
- 208000007159 Trisomy 18 Syndrome Diseases 0.000 description 18
- 201000009928 Patau syndrome Diseases 0.000 description 17
- 206010044686 Trisomy 13 Diseases 0.000 description 17
- 208000006284 Trisomy 13 Syndrome Diseases 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 230000002068 genetic effect Effects 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- 201000011510 cancer Diseases 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 15
- 210000003765 sex chromosome Anatomy 0.000 description 15
- 230000005945 translocation Effects 0.000 description 14
- 239000013060 biological fluid Substances 0.000 description 13
- 238000004422 calculation algorithm Methods 0.000 description 13
- 238000013467 fragmentation Methods 0.000 description 13
- 238000006062 fragmentation reaction Methods 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 12
- 230000036541 health Effects 0.000 description 12
- 208000030454 monosomy Diseases 0.000 description 12
- 238000000746 purification Methods 0.000 description 12
- 229920002477 rna polymer Polymers 0.000 description 12
- 238000004364 calculation method Methods 0.000 description 11
- 239000012530 fluid Substances 0.000 description 11
- 150000002500 ions Chemical class 0.000 description 11
- 230000035935 pregnancy Effects 0.000 description 11
- 206010036790 Productive cough Diseases 0.000 description 10
- 230000005856 abnormality Effects 0.000 description 10
- 238000001574 biopsy Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000000670 limiting effect Effects 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 210000003802 sputum Anatomy 0.000 description 10
- 208000024794 sputum Diseases 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 210000002700 urine Anatomy 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 108091092356 cellular DNA Proteins 0.000 description 9
- 238000009396 hybridization Methods 0.000 description 9
- 238000013439 planning Methods 0.000 description 9
- 210000001138 tear Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000003322 aneuploid effect Effects 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 8
- 230000002559 cytogenic effect Effects 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000003793 prenatal diagnosis Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 238000007619 statistical method Methods 0.000 description 8
- 238000010200 validation analysis Methods 0.000 description 8
- 208000037068 Abnormal Karyotype Diseases 0.000 description 7
- 102000004594 DNA Polymerase I Human genes 0.000 description 7
- 108010017826 DNA Polymerase I Proteins 0.000 description 7
- -1 cell-free DNA Chemical class 0.000 description 7
- 238000009795 derivation Methods 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 238000001962 electrophoresis Methods 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002669 amniocentesis Methods 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 238000009223 counseling Methods 0.000 description 6
- 238000013461 design Methods 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 238000005259 measurement Methods 0.000 description 6
- 239000013610 patient sample Substances 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- 230000002441 reversible effect Effects 0.000 description 6
- 210000003296 saliva Anatomy 0.000 description 6
- 238000012795 verification Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 5
- 208000031404 Chromosome Aberrations Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 239000012895 dilution Substances 0.000 description 5
- 208000016361 genetic disease Diseases 0.000 description 5
- 210000003917 human chromosome Anatomy 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 238000003780 insertion Methods 0.000 description 5
- 230000037431 insertion Effects 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 208000026485 trisomy X Diseases 0.000 description 5
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 description 4
- 208000026817 47,XYY syndrome Diseases 0.000 description 4
- 108091093088 Amplicon Proteins 0.000 description 4
- 208000000398 DiGeorge Syndrome Diseases 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- 208000036626 Mental retardation Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108091092878 Microsatellite Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 208000028831 congenital heart disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000002405 diagnostic procedure Methods 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 238000007672 fourth generation sequencing Methods 0.000 description 4
- 235000020256 human milk Nutrition 0.000 description 4
- 210000004251 human milk Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 230000000977 initiatory effect Effects 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 230000008520 organization Effects 0.000 description 4
- 238000002203 pretreatment Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 230000003252 repetitive effect Effects 0.000 description 4
- 239000004065 semiconductor Substances 0.000 description 4
- 238000007841 sequencing by ligation Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108700028369 Alleles Proteins 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 3
- 208000002330 Congenital Heart Defects Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 108010034791 Heterochromatin Proteins 0.000 description 3
- 201000006347 Intellectual Disability Diseases 0.000 description 3
- 108091093037 Peptide nucleic acid Proteins 0.000 description 3
- 201000001388 Smith-Magenis syndrome Diseases 0.000 description 3
- 206010053871 Trisomy 8 Diseases 0.000 description 3
- 206010071547 Trisomy 9 Diseases 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 210000001061 forehead Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000012224 gene deletion Methods 0.000 description 3
- 238000013412 genome amplification Methods 0.000 description 3
- 210000004458 heterochromatin Anatomy 0.000 description 3
- 210000001182 human Y chromosome Anatomy 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 230000036244 malformation Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 238000012175 pyrosequencing Methods 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000002254 stillbirth Diseases 0.000 description 3
- 231100000537 stillbirth Toxicity 0.000 description 3
- 230000008093 supporting effect Effects 0.000 description 3
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 3
- 208000034298 trisomy chromosome 8 Diseases 0.000 description 3
- 238000012176 true single molecule sequencing Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- IJRKANNOPXMZSG-SSPAHAAFSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IJRKANNOPXMZSG-SSPAHAAFSA-N 0.000 description 2
- 208000009575 Angelman syndrome Diseases 0.000 description 2
- 206010003805 Autism Diseases 0.000 description 2
- 208000020706 Autistic disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 108091061744 Cell-free fetal DNA Proteins 0.000 description 2
- 208000011359 Chromosome disease Diseases 0.000 description 2
- 208000032170 Congenital Abnormalities Diseases 0.000 description 2
- 206010010356 Congenital anomaly Diseases 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- 206010012559 Developmental delay Diseases 0.000 description 2
- 208000012239 Developmental disease Diseases 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 238000006424 Flood reaction Methods 0.000 description 2
- 206010021118 Hypotonia Diseases 0.000 description 2
- 208000004706 Jacobsen Distal 11q Deletion Syndrome Diseases 0.000 description 2
- 208000017924 Klinefelter Syndrome Diseases 0.000 description 2
- 208000030979 Language Development disease Diseases 0.000 description 2
- 208000010961 Monosomy 21 Diseases 0.000 description 2
- 208000019209 Monosomy 22 Diseases 0.000 description 2
- 208000034702 Multiple pregnancies Diseases 0.000 description 2
- 208000007379 Muscle Hypotonia Diseases 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 206010068786 Overlap syndrome Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 2
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 2
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 101000757182 Saccharomyces cerevisiae Glucoamylase S2 Proteins 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 208000026487 Triploidy Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000007698 birth defect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000004252 chorionic villi Anatomy 0.000 description 2
- 208000024971 chromosomal disease Diseases 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002011 intestinal secretion Anatomy 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 231100000533 low birth weight Toxicity 0.000 description 2
- 208000018773 low birth weight Diseases 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000031864 metaphase Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000013188 needle biopsy Methods 0.000 description 2
- 230000005257 nucleotidylation Effects 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000002972 pentoses Chemical group 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 102000054765 polymorphisms of proteins Human genes 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 238000007480 sanger sequencing Methods 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 238000000527 sonication Methods 0.000 description 2
- 208000000995 spontaneous abortion Diseases 0.000 description 2
- 238000010972 statistical evaluation Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000004627 transmission electron microscopy Methods 0.000 description 2
- 206010044689 trisomy 22 Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 230000036266 weeks of gestation Effects 0.000 description 2
- AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 1
- PIINGYXNCHTJTF-UHFFFAOYSA-N 2-(2-azaniumylethylamino)acetate Chemical compound NCCNCC(O)=O PIINGYXNCHTJTF-UHFFFAOYSA-N 0.000 description 1
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- IRLPACMLTUPBCL-KQYNXXCUSA-N 5'-adenylyl sulfate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OS(O)(=O)=O)[C@@H](O)[C@H]1O IRLPACMLTUPBCL-KQYNXXCUSA-N 0.000 description 1
- 208000017976 8p23.1 duplication syndrome Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 208000025637 Autosomal monosomy Diseases 0.000 description 1
- 208000018311 Autosomal trisomy Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000016718 Chromosome Inversion Diseases 0.000 description 1
- 206010009269 Cleft palate Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108020004394 Complementary RNA Proteins 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 206010066054 Dysmorphism Diseases 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 101710181043 Endonuclease 2 Proteins 0.000 description 1
- 108010022894 Euchromatin Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241000691979 Halcyon Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 208000029279 Jacobsen Syndrome Diseases 0.000 description 1
- 208000030653 Jaw disease Diseases 0.000 description 1
- 206010023230 Joint stiffness Diseases 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000037699 Monosomy 18p Diseases 0.000 description 1
- 208000016684 Mosaic monosomy X Diseases 0.000 description 1
- 208000010610 Mosaic trisomy 8 Diseases 0.000 description 1
- 101100113998 Mus musculus Cnbd2 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 208000003019 Neurofibromatosis 1 Diseases 0.000 description 1
- 208000024834 Neurofibromatosis type 1 Diseases 0.000 description 1
- 102100030569 Nuclear receptor corepressor 2 Human genes 0.000 description 1
- 101710153660 Nuclear receptor corepressor 2 Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 101150038744 PMP22 gene Proteins 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002151 Pleural effusion Diseases 0.000 description 1
- 208000032236 Predisposition to disease Diseases 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 101000804877 Schizosaccharomyces pombe (strain 972 / ATCC 24843) 5'-3' exoribonuclease 1 Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000036623 Severe mental retardation Diseases 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 208000035199 Tetraploidy Diseases 0.000 description 1
- 208000020741 Tetrasomy 12p Diseases 0.000 description 1
- 101100388071 Thermococcus sp. (strain GE8) pol gene Proteins 0.000 description 1
- 206010062757 Trisomy 15 Diseases 0.000 description 1
- 206010053925 Trisomy 17 Diseases 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000000260 Warts Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000006254 Wolf-Hirschhorn Syndrome Diseases 0.000 description 1
- 206010056894 XYY syndrome Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 150000003838 adenosines Chemical class 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 210000001776 amniocyte Anatomy 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 208000029560 autism spectrum disease Diseases 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 208000015241 chromosome 13q trisomy Diseases 0.000 description 1
- 208000004664 chromosome 18p deletion syndrome Diseases 0.000 description 1
- 108091092240 circulating cell-free DNA Proteins 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 206010009259 cleft lip Diseases 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000003184 complementary RNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 208000022734 developmental defect during embryogenesis Diseases 0.000 description 1
- 231100000020 developmental retardation Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000012553 document review Methods 0.000 description 1
- 231100001129 embryonic lethality Toxicity 0.000 description 1
- 238000004836 empirical method Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 210000000632 euchromatin Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- LIYGYAHYXQDGEP-UHFFFAOYSA-N firefly oxyluciferin Natural products Oc1csc(n1)-c1nc2ccc(O)cc2s1 LIYGYAHYXQDGEP-UHFFFAOYSA-N 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 238000002509 fluorescent in situ hybridization Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010448 genetic screening Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 230000010370 hearing loss Effects 0.000 description 1
- 231100000888 hearing loss Toxicity 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003426 interchromosomal effect Effects 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000019689 luncheon sausage Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000003188 neurobehavioral effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 201000003738 orofaciodigital syndrome VIII Diseases 0.000 description 1
- JJVOROULKOMTKG-UHFFFAOYSA-N oxidized Photinus luciferin Chemical compound S1C2=CC(O)=CC=C2N=C1C1=NC(=O)CS1 JJVOROULKOMTKG-UHFFFAOYSA-N 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 208000014689 partial deletion of chromosome 10 Diseases 0.000 description 1
- 208000014813 partial deletion of chromosome 18 Diseases 0.000 description 1
- 208000014690 partial deletion of chromosome 5 Diseases 0.000 description 1
- 208000011306 partial deletion of the short arm of chromosome 10 Diseases 0.000 description 1
- 208000034352 partial segmental duplication Diseases 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 208000036897 pentasomy Diseases 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 210000005059 placental tissue Anatomy 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 239000012521 purified sample Substances 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000031893 sensory processing Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 231100001055 skeletal defect Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 108010062513 snake venom phosphodiesterase I Proteins 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 208000011908 tetrasomy Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical group [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002569 water oil cream Substances 0.000 description 1
- 238000012070 whole genome sequencing analysis Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/10—Ploidy or copy number detection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B20/20—Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/10—Sequence alignment; Homology search
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B30/00—ICT specially adapted for sequence analysis involving nucleotides or amino acids
- G16B30/20—Sequence assembly
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Medical Informatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361836057P | 2013-06-17 | 2013-06-17 | |
| US61/836,057 | 2013-06-17 | ||
| PCT/US2014/042785 WO2014204991A1 (en) | 2013-06-17 | 2014-06-17 | Method for determining copy number variations in sex chromosomes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081704A Division JP7021148B2 (ja) | 2013-06-17 | 2019-04-23 | 性染色体におけるコピー数変異を判定するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016526380A JP2016526380A (ja) | 2016-09-05 |
| JP2016526380A5 JP2016526380A5 (enExample) | 2017-07-27 |
| JP6521956B2 true JP6521956B2 (ja) | 2019-05-29 |
Family
ID=51205579
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016521519A Expired - Fee Related JP6521956B2 (ja) | 2013-06-17 | 2014-06-17 | 性染色体におけるコピー数変異を判定するための方法 |
| JP2019081704A Expired - Fee Related JP7021148B2 (ja) | 2013-06-17 | 2019-04-23 | 性染色体におけるコピー数変異を判定するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019081704A Expired - Fee Related JP7021148B2 (ja) | 2013-06-17 | 2019-04-23 | 性染色体におけるコピー数変異を判定するための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20140371078A1 (enExample) |
| EP (2) | EP3011052B1 (enExample) |
| JP (2) | JP6521956B2 (enExample) |
| CN (1) | CN105722994B (enExample) |
| AU (1) | AU2014281635B2 (enExample) |
| CA (1) | CA2915626A1 (enExample) |
| IL (1) | IL242956B (enExample) |
| WO (1) | WO2014204991A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102373647B1 (ko) * | 2013-10-21 | 2022-03-11 | 베리나타 헬스, 인코포레이티드 | 사본수 변동을 결정함에 있어서 검출의 감수성을 향상시키기 위한 방법 |
| US10318704B2 (en) | 2014-05-30 | 2019-06-11 | Verinata Health, Inc. | Detecting fetal sub-chromosomal aneuploidies |
| EP3567120B1 (en) | 2014-12-12 | 2020-08-19 | Verinata Health, Inc. | Using cell-free dna fragment size to determine copy number variations |
| WO2016109364A1 (en) * | 2014-12-29 | 2016-07-07 | Counsyl, Inc. | Method for determining genotypes in regions of high homology |
| CA2985135A1 (en) * | 2015-05-06 | 2016-11-10 | Seracare Life Sciences, Inc. | Liposomal preparations for non-invasive-prenatal or cancer screening |
| WO2017094941A1 (ko) * | 2015-12-04 | 2017-06-08 | 주식회사 녹십자지놈 | 핵산의 혼합물을 포함하는 샘플에서 복제수 변이를 결정하는 방법 |
| FI3408376T3 (fi) * | 2016-01-31 | 2025-10-08 | Hadasit Med Res Service | Autosomisesti identtiset pluripotentit kantasolupopulaatiot, joilla on ei-identtinen sukupuolikromosomikoostumus, ja niiden käyttötarkoitukset |
| US10095831B2 (en) | 2016-02-03 | 2018-10-09 | Verinata Health, Inc. | Using cell-free DNA fragment size to determine copy number variations |
| JP7448310B2 (ja) * | 2016-07-06 | 2024-03-12 | ガーダント ヘルス， インコーポレイテッド | セルフリー核酸のフラグメントームプロファイリングのための方法 |
| EP3497218B1 (en) * | 2016-08-08 | 2022-03-16 | Karius, Inc. | Reduction of signal from contaminant nucleic acids |
| AU2017332381A1 (en) * | 2016-09-22 | 2019-04-18 | Illumina, Inc. | Somatic copy number variation detection |
| TWI603082B (zh) * | 2016-09-30 | 2017-10-21 | 有勁生物科技股份有限公司 | 非侵入式胎兒性徵異常檢測系統及其方法與非侵入式胎兒性徵檢測系統及其方法 |
| EP3541934B1 (en) * | 2016-11-17 | 2024-04-10 | LGC Clinical Diagnostics, Inc. | Methods for preparing dna reference material and controls |
| CN106845154B (zh) * | 2016-12-29 | 2022-04-08 | 浙江安诺优达生物科技有限公司 | 一种用于ffpe样本拷贝数变异检测的装置 |
| US11342047B2 (en) | 2017-04-21 | 2022-05-24 | Illumina, Inc. | Using cell-free DNA fragment size to detect tumor-associated variant |
| CN107119145A (zh) * | 2017-07-13 | 2017-09-01 | 深圳瑞科生物科技有限公司 | 一种基于ddPCR定量检测ctDNA的方法 |
| CN109390039B (zh) * | 2017-08-11 | 2020-10-16 | 深圳华大基因股份有限公司 | 一种统计dna拷贝数信息的方法、装置及存储介质 |
| CN111052249B (zh) * | 2017-09-15 | 2024-04-05 | 深圳华大智造科技股份有限公司 | 确定预定染色体保守区域的方法、确定样本基因组中是否存在拷贝数变异的方法、系统和计算机可读介质 |
| US11168356B2 (en) * | 2017-11-02 | 2021-11-09 | The Chinese University Of Hong Kong | Using nucleic acid size range for noninvasive cancer detection |
| CN110800061B (zh) | 2017-11-16 | 2024-10-11 | 伊鲁米那股份有限公司 | 用于确定微卫星不稳定性的系统和方法 |
| CN108427864B (zh) * | 2018-02-14 | 2019-01-29 | 南京世和基因生物技术有限公司 | 一种拷贝数变异的检测方法、装置以及计算机可读介质 |
| US12154661B2 (en) | 2018-03-22 | 2024-11-26 | The Regents Of The University Of Michigan | Method and apparatus for analysis of chromatin interaction data |
| TW202410055A (zh) * | 2018-06-01 | 2024-03-01 | 美商格瑞爾有限責任公司 | 用於資料分類之卷積神經網路系統及方法 |
| CN109136371B (zh) * | 2018-07-25 | 2019-11-01 | 南京世和基因生物技术有限公司 | 一种放疗疗效和毒性反应相关基因组合、检测探针库以及检测试剂盒 |
| KR102405245B1 (ko) * | 2018-07-27 | 2022-06-07 | 주식회사 지씨지놈 | 전장유전체 시퀀싱 기반의 염색체 이상 검출 방법 및 그 용도 |
| US11581062B2 (en) | 2018-12-10 | 2023-02-14 | Grail, Llc | Systems and methods for classifying patients with respect to multiple cancer classes |
| CN113795887A (zh) * | 2019-03-10 | 2021-12-14 | 阿尔缇玛基因组学公司 | 用于序列判定的方法和系统 |
| CN111755066B (zh) * | 2019-03-27 | 2022-10-18 | 欧蒙医学诊断（中国）有限公司 | 一种拷贝数变异的检测方法和实施该方法的设备 |
| CN110534202A (zh) * | 2019-08-21 | 2019-12-03 | 江南大学附属医院（无锡市第四人民医院） | 一种针对Sox10在三阴性乳腺癌中的表达进行分析的系统 |
| IL298458A (en) | 2020-05-22 | 2023-01-01 | Aqtual Inc | Methods for characterizing cell-free nucleic acid fragments |
| CN113409885B (zh) * | 2021-06-21 | 2022-09-20 | 天津金域医学检验实验室有限公司 | 一种自动化数据处理以及作图方法及系统 |
| CN114420208B (zh) * | 2022-02-28 | 2023-04-18 | 上海亿康医学检验所有限公司 | 一种用于鉴定核酸样本中cnv的方法和装置 |
| JP7331325B1 (ja) | 2022-08-30 | 2023-08-23 | 株式会社seeDNA | ２種以上の検査を実施可能な遺伝学的解析方法 |
| CN115273984B (zh) * | 2022-09-30 | 2022-11-29 | 北京诺禾致源科技股份有限公司 | 鉴定基因组串联重复区域的方法及装置 |
| CN115394359B (zh) * | 2022-10-27 | 2023-03-24 | 北京大学第三医院（北京大学第三临床医学院） | 一种通过转录组检测单细胞染色体拷贝数变异方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7235358B2 (en) * | 2001-06-08 | 2007-06-26 | Expression Diagnostics, Inc. | Methods and compositions for diagnosing and monitoring transplant rejection |
| CA2668818C (en) | 2006-10-10 | 2018-06-26 | Xenomics, Inc. | Compositions, methods and kits for isolating nucleic acids from body fluids using anion exchange media |
| US8262900B2 (en) | 2006-12-14 | 2012-09-11 | Life Technologies Corporation | Methods and apparatus for measuring analytes using large scale FET arrays |
| CN101889074A (zh) | 2007-10-04 | 2010-11-17 | 哈尔西恩莫尔丘勒公司 | 采用电子显微镜对核酸聚合物测序 |
| GB0811500D0 (en) * | 2008-06-20 | 2008-07-30 | Univ Cardiff | Method of determining DNA copy number |
| WO2011050341A1 (en) * | 2009-10-22 | 2011-04-28 | National Center For Genome Resources | Methods and systems for medical sequencing analysis |
| WO2011090556A1 (en) | 2010-01-19 | 2011-07-28 | Verinata Health, Inc. | Methods for determining fraction of fetal nucleic acid in maternal samples |
| EP3006573B1 (en) | 2010-01-19 | 2018-03-07 | Verinata Health, Inc | Methods for determining fraction of fetal nucleic acids in maternal samples |
| US9260745B2 (en) | 2010-01-19 | 2016-02-16 | Verinata Health, Inc. | Detecting and classifying copy number variation |
| US20120046877A1 (en) * | 2010-07-06 | 2012-02-23 | Life Technologies Corporation | Systems and methods to detect copy number variation |
| US20120034603A1 (en) * | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
| JP6153874B2 (ja) * | 2011-02-09 | 2017-06-28 | ナテラ， インコーポレイテッド | 非侵襲的出生前倍数性呼び出しのための方法 |
| CN103003447B (zh) * | 2011-07-26 | 2020-08-25 | 维里纳塔健康公司 | 用于确定样品中存在或不存在不同非整倍性的方法 |
| US8688388B2 (en) * | 2011-10-11 | 2014-04-01 | Sequenom, Inc. | Methods and processes for non-invasive assessment of genetic variations |
| US9538439B2 (en) * | 2013-05-10 | 2017-01-03 | Qualcomm Incorporated | Method and apparatus for estimating an achievable link throughput based on assistance information |
-
2014
- 2014-06-17 CA CA2915626A patent/CA2915626A1/en active Pending
- 2014-06-17 WO PCT/US2014/042785 patent/WO2014204991A1/en not_active Ceased
- 2014-06-17 EP EP14739612.1A patent/EP3011052B1/en not_active Not-in-force
- 2014-06-17 AU AU2014281635A patent/AU2014281635B2/en not_active Ceased
- 2014-06-17 JP JP2016521519A patent/JP6521956B2/ja not_active Expired - Fee Related
- 2014-06-17 US US14/307,143 patent/US20140371078A1/en active Pending
- 2014-06-17 CN CN201480045591.2A patent/CN105722994B/zh not_active Expired - Fee Related
- 2014-06-17 EP EP19172284.2A patent/EP3543354B1/en not_active Not-in-force
-
2015
- 2015-12-06 IL IL24295615A patent/IL242956B/en active IP Right Grant
-
2019
- 2019-04-23 JP JP2019081704A patent/JP7021148B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HK1223988A1 (en) | 2017-08-11 |
| CA2915626A1 (en) | 2014-12-24 |
| AU2014281635A1 (en) | 2016-02-11 |
| EP3011052B1 (en) | 2019-05-22 |
| CN105722994B (zh) | 2020-12-18 |
| CN105722994A (zh) | 2016-06-29 |
| JP7021148B2 (ja) | 2022-02-16 |
| JP2019153332A (ja) | 2019-09-12 |
| JP2016526380A (ja) | 2016-09-05 |
| US20140371078A1 (en) | 2014-12-18 |
| EP3011052A1 (en) | 2016-04-27 |
| EP3543354A1 (en) | 2019-09-25 |
| IL242956B (en) | 2019-10-31 |
| EP3543354B1 (en) | 2022-01-19 |
| AU2014281635B2 (en) | 2020-05-28 |
| WO2014204991A1 (en) | 2014-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6521956B2 (ja) | 性染色体におけるコピー数変異を判定するための方法 | |
| AU2020200728B2 (en) | Method for improving the sensitivity of detection in determining copy number variations | |
| US12217827B2 (en) | Detecting fetal sub-chromosomal aneuploidies | |
| HK40098511A (en) | Method for improving the sensitivity of detection in determining copy number variations | |
| HK40013205B (en) | Method for generating a masked reference sequence of the y chromosome | |
| HK40013205A (en) | Method for generating a masked reference sequence of the y chromosome | |
| HK1223988B (en) | Method for determining copy number variations in sex chromosomes | |
| HK1228052B (en) | Method for improving the sensitivity of detection in determining copy number variations | |
| HK1228052A1 (en) | Method for improving the sensitivity of detection in determining copy number variations | |
| HK40033718A (en) | Detecting, optionally fetal, sub-chromosomal aneuploidies and copy number variations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170613 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170613 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180711 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20181009 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181207 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190408 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20190423 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6521956 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |